Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens

ABSTRACT: Functional genomics screens have revealed cancer gene dependencies, but cell culture misses vulnerabilities driven by the tumor microenvironment. We implemented CRISPR-StAR (Stochastic Activation by Recombination), an inducible pooled screening system that activates gene knockout after tumor engraftment and provides matched internal controls for guide-level normalization. Using barcode-embedded sequencing and Bayesian analysis, we screened a 30,000-sgRNA library in A549 xenografts and achieved reproducible dropout and enrichment phenotypes using just ~30 tumors. Across additional xenograft models, single tumors yielded reliable functional annotation for ~1,000 genes leveraging within-tumor normalization. Comparing in vivo and in vitro screens uncovered tumor-suppressor effects detectable only in vivo; for example KMT2C and KMT2D knockouts produced contrasting tumor growth and transcriptional programs. Together with our R analysis package, CRISPR-StAR enables scalable in vivo dependency mapping that complements in vitro resources and reduces animal use up to sevenfold versus conventional dropout screens, improving overall methodological rigor at genome-scale clonal resolution.

ORGANISM(S): Homo sapiens

PROVIDER: GSE328830 | GEO | 2026/04/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CRISPR-MIP replaces PCR and reveals GC and oversampling bias in pooled CRISPR screens

Project description:This is data for the evaluation of a new way of counting sgRNAs in CRISPR screens using padlock probes and UMIs. It is compared to the typical PCR-based approach. In particular, a dropout screen was performed in MiaPaCa-2 cells using the Human Kinome CRISPR pooled library (Addgene #75314)

2024-08-18 | E-MTAB-14379 | biostudies-arrayexpress

CRISPR screens are feasible in TP53 wild-type cells

Project description:CRISPR-Cas9 genome-wide screens were performed in retinal pigment epithelial cells (RPE1) with either wild-type TP53 gene, or a TP53-null background. Results show wild-type TP53 has minimal impact on the efficiency of CRISPR dropout screens.

2019-04-30 | GSE128210 | GEO

CRISPR screen targeting druggable genes in 4T1 mouse cells

Project description:4T1 mouse tumor cells were screened with a CRISPR library concurrently in vivo in both SCID and immunocompetent mice. Screens were also carried out in vitro.

2021-09-01 | E-MTAB-10731 | biostudies-arrayexpress

Homo sapiens

Project description:PARALLEL IN VIVO AND IN VITRO MELANOMA RNAi DROPOUT SCREENS

| PRJNA262511 | ENA

Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens

Project description:Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens

| PRJNA1456609 | ENA

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 2)

Project description:Pooled genetic screening with CRISPR/Cas9 has enabled genome-wide high-resolution assignment of genes to phenotypes. To assess the effect of a given genetic perturbation, each sgRNA must be evaluated in hundreds of cells to overcome stochastic genetic drift and obtain robust results. In complex models that display particularly high heterogeneity, such as organoids or tumors transplanted into mice however, sufficient representation typically requires unreasonable scaling, thus preventing genome-wide screens at high resolution. Here we present CRISPR-StAR, a screening paradigm that overcomes intrinsic and extrinsic heterogeneity as well as genetic drift in bottlenecks by leveraging internal controls generated through activating sgRNAs only in half of the progenies of each cell. We use CRISPR-StAR to reveal in vivo-specific genetic dependencies in a genome-wide screen in mouse melanoma. Benchmarking to a conventional screening setup highlights the improved data quality this technology delivers. We anticipate CRISPR-StAR to set a new standard for genetic screening in complex models, foremost in vivo.

2024-11-05 | GSE262308 | GEO

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 1)

2024-11-05 | GSE262307 | GEO

PARALLEL IN VIVO AND IN VITRO MELANOMA RNAi DROPOUT SCREENS

2014-09-30 | GSE61826 | GEO

PARALLEL IN VIVO AND IN VITRO MELANOMA RNAi DROPOUT SCREENS

Project description:To identify factors preferentially necessary to drive tumor expansion we performed parallel in vitro and in vivo negative selection shRNA screens. Melanoma cells harboring shRNAs targeting several DNA Damage Response (DDR) kinases had a greater selective disadvantage in vivo than in vitro, indicating an essential contribution of these factors during tumor expansion. In growing tumors, DDR kinases were activated following hypoxia. Correspondingly, depletion or pharmacologic inhibition of DDR kinases was toxic to melanoma cells, including those that were resistant to BRAF inhibitor, and this could be enhanced by angiogenesis blockade. These results reveal that hypoxia sensitizes melanomas to targeted inhibition of the DDR and illustrate the utility of in vivo shRNA dropout screens for identification of pharmacologically tractable targets. A lentivirus-based kinome shRNA library (four pools) was used to transduce 888mel cells (MOI<0.2). After puromycin selection (1μg/ml), two reference samples were collected as controls. Next, tumor cells (5x105 per injection) were either injected s.c. into 6 NSG mice or plated into 6 independent plates (5x105) for in vitro culture. Tumors were removed from the mice and genomic DNA used to recover shRNAs by PCR amplification followed by deep sequencing. Three analyses were performed independently in parallel: (1) Tumors versus cultured cells (Log2 Fold Change < -1); (2) Tumors versus references (Log2 Fold Change < -2.5) and (3) Cultured cells versus references (Log2 Fold Change < -2.5). Genes targeted with at least 2 shRNAs in each of the analysis were considered hits with an enhanced in vivo effect.

2014-09-30 | E-GEOD-61826 | biostudies-arrayexpress

Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer

Project description:Lung cancer cells rely on protein homeostasis regulators, particularly the ubiquitin-proteasome system (UPS), to sustain malignancy. Genetic alterations in UPS components, such as E3 ubiquitin ligases (E3s) and deubiquitinating enzymes (DUBs), are common and create context-dependent therapeutic dependencies. To investigate how these changes drive tumor formation, we conducted CRISPR screens on metabolically stressed murine lung cancer models and identified specific cancer vulnerabilities, including KEAP1. Although KEAP1 is frequently mutated in aggressive non-small cell lung cancers (NSCLC, ~15%), our findings reveal an unexpected proto-oncogenic role for KEAP1 in a genetically defined subset of NSCLC. Mechanistically, Keap1 deletion activated NRF2 and upregulated Aldh3a1. This led to elevated NADH/NAD⁺ ratios, triggered reductive stress, and suppressed tumor growth. Given the poor prognosis of KEAP1-mutated patients, combinatorial CRISPR dropout screens revealed druggable E3s and DUBs as Keap1-dependent co-vulnerabilities. Notably, depleting these co-dependencies such as the E3 ligases Herc2, Ubr4 and Huwe1 ablated the in vivo development of Keap1-inactivated tumors. We demonstrate that targeting the UPS represents an underexplored, promising therapeutic approach for patients with KEAP1-inactivated tumors, especially under metabolic stress.

2026-01-23 | GSE306334 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data